Mucormycosis, a secondary fungal infection, gained much attention in the ongoing COVID-19 pandemic. This deadly infection has a high all-cause mortality rate and imposes a significant economic, epidemiological, and humanistic burden on the patients and healthcare system. Evidence from the published epidemiological studies showed the varying prevalence of COVID-19-associated mucormycosis (CAM). This study aims to compute the pooled prevalence of CAM and other associated clinical outcomes. MEDLINE, Embase, Cochrane COVID-19 Study Register, and WHO COVID-19 databases were scanned to retrieve the relevant articles until August 2021. All studies reporting the prevalence of mucormycosis among COVID-19 patients were eligible for inclusion. Two investigators independently screened the articles against the selection criteria, extracted the data, and performed the quality assessment using the JBI tool. The pooled prevalence of CAM was the primary outcome, and the pooled prevalence of diabetes, steroid exposure, and the mortality rate were the secondary outcomes of interest. Comprehensive Meta-Analysis software version 2 was used for performing the meta-analysis. This meta-analysis comprised six studies with a pooled sample size of 52,916 COVID-19 patients with a mean age of 62.12 ± 9.69 years. The mean duration of mucormycosis onset was 14.59 ± 6.88 days after the COVID-19 diagnosis. The pooled prevalence of CAM (seven cases per 1000 patients) was 50 times higher than the highest recorded background of mucormycosis (0.14 cases per 1000 patients). A high mortality rate was found among CAM patients with a pooled prevalence rate of 29.6% (95% CI: 17.2-45.9%). Optimal glycemic control and the judicious use of steroids should be the approach for tackling rising CAM cases.

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Department of Public Health Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

International Clinical Research Center Molecular Control of Cell Signaling Group St Anne's University Hospital 656 91 Brno Czech Republic

Menzies Institute for Medical Research University of Tasmania 17 Liverpool St Hobart TAS 7000 Australia

Zobrazit více v PubMed

Skiada A., Pavleas I., Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. J. Fungi. 2020;6:265. doi: 10.3390/jof6040265. PubMed DOI PMC

Prakash H., Chakrabarti A. Global Epidemiology of Mucormycosis. J. Fungi. 2019;5:26. doi: 10.3390/jof5010026. PubMed DOI PMC

Serris A., Danion F., Lanternier F. Disease Entities in Mucormycosis. J. Fungi. 2019;5:23. doi: 10.3390/jof5010023. PubMed DOI PMC

Prakash H., Ghosh A.K., Rudramurthy S., Singh P., Xess I., Savio J., Pamidimukkala U., Jillwin J., Varma S., Das A., et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med. Mycol. 2019;57:395–402. doi: 10.1093/mmy/myy060. PubMed DOI

Roden M.M., Zaoutis T.E., Buchanan W.L., Knudsen T.A., Sarkisova T.A., Schaufele R.L., Sein M., Sein T., Chiou C.C., Chu J.H., et al. Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases. Clin. Infect. Dis. 2005;41:634–653. doi: 10.1086/432579. PubMed DOI

Moreira J., Varon A., Galhardo M.C., Santos F., Lyra M., Castro R., Oliveira R., Lamas C.C. The burden of mucormycosis in HIV-infected patients: A systematic review. J. Infect. 2016;73:181–188. doi: 10.1016/j.jinf.2016.06.013. PubMed DOI

Song Y., Qiao J., Giovanni G., Liu G., Yang H., Wu J., Chen J. Mucormycosis in renal transplant recipients: Review of 174 reported cases. BMC Infect. Dis. 2017;17:1–6. doi: 10.1186/s12879-017-2381-1. PubMed DOI PMC

Muthu V., Agarwal R., Dhooria S., Sehgal I.S., Prasad K.T., Aggarwal A.N., Chakrabarti A. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin. Microbiol. Infect. 2021;27:538–549. doi: 10.1016/j.cmi.2020.12.035. PubMed DOI

Wand O., Unterman A., Izhakian S., Fridel L., Kramer M.R. Mucormycosis in lung transplant recipients: A systematic review of the literature and a case series. Clin. Transplant. 2019;34:e13774. doi: 10.1111/ctr.13774. PubMed DOI

Ueno R., Nishimura S., Fujimoto G., Ainiwaer D. The disease burden of mucormycosis in Japan: Results from a systematic literature review and retrospective database study. Curr. Med. Res. Opin. 2021;37:253–260. doi: 10.1080/03007995.2020.1846510. PubMed DOI

Jeong W., Keighley C., Wolfe R., Lee W.L., Slavin M., Kong D.C., Chen S.C.-A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019;25:26–34. doi: 10.1016/j.cmi.2018.07.011. PubMed DOI

Saegeman V., Maertens J., Meersseman W., Spriet I., Verbeken E., Lagrou K. Increasing Incidence of Mucormycosis in University Hospital, Belgium—Volume 16, Number 9—September 2010—Emerging Infectious Diseases journal—CDC. Emerg. Infect. Dis. 2010;16:1456–1458. doi: 10.3201/eid1609.100276. PubMed DOI PMC

Lewis R.E., Cahyame-Zuniga L., Leventakos K., Chamilos G., Ben-Ami R., Tamboli P., Tarrand J., Bodey G.P., Luna M., Kontoyiannis D.P. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: A 20-year autopsy study. Mycoses. 2013;56:638–645. doi: 10.1111/myc.12081. PubMed DOI

Guinea J., Escribano P., Vena A., Muñoz P., Martínez-Jiménez M.D.C., Padilla B., Bouza E. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS ONE. 2017;12:e0179136. doi: 10.1371/journal.pone.0179136. PubMed DOI PMC

Ambrosioni J., Bouchuiguir-Wafa K., Garbino J. Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors. Int. J. Infect. Dis. 2010;14:e100–e103. doi: 10.1016/j.ijid.2009.11.024. PubMed DOI

Bitar D., Van Cauteren D., Lanternier F., Dannaoui E., Che D., Dromer F., Desenclos J.-C., Lortholary O. Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006—Volume 15, Number 9—September 2009—Emerging Infectious Diseases journal—CDC. Emerg. Infect. Dis. 2009;15:1395–1401. doi: 10.3201/eid1509.090334. PubMed DOI PMC

Chakrabarti A., Das A., Sharma A., Panda N., Das S., Gupta K., Sakhuja V. Ten Years’ Experience in Zygomycosis at a Tertiary Care Centre in India. J. Infect. 2001;42:261–266. doi: 10.1053/jinf.2001.0831. PubMed DOI

Chakrabarti A., Das A., Mandal J., Shivaprakash M.R., George V.K., Tarai B., Rao P., Panda N., Verma S.C., Sakhuja V. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 2006;44:335–342. doi: 10.1080/13693780500464930. PubMed DOI

Chakrabarti A., Chatterjee S.S., Das A., Panda N., Shivaprakash M.R., Kaur A., Varma S.C., Singhi S., Bhansali A., Sakhuja V. Invasive zygomycosis in India: Experience in a tertiary care hospital. Postgrad. Med. J. 2009;85:573–581. doi: 10.1136/pgmj.2008.076463. PubMed DOI

Chander J., Kaur M., Singla N., Punia R.P.S., Singhal S.K., Attri A.K., Alastruey-Izquierdo A., Stchigel A.M., Cano-Lira J.F., Guarro J. Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India. J. Fungi. 2018;4:46. doi: 10.3390/jof4020046. PubMed DOI PMC

Leading International Fungal Education (LIFE) How Common Are Fungal Diseases. Leading International Fungal Education (LIFE); Cheshire, UK: 2019.

Centers for Disease Control and Prevention (CDC) Lesson 1—Section 5. [(accessed on 29 September 2021)]; Available online: https://www.cdc.gov/csels/dsepd/ss1978/lesson1/section5.html.

Millon L., Scherer E., Rocchi S., Bellanger A.-P. Molecular Strategies to Diagnose Mucormycosis. J. Fungi. 2019;5:24. doi: 10.3390/jof5010024. PubMed DOI PMC

Kontoyiannis D.P., Yang H., Song J., Kelkar S.S., Yang X., Azie N., Harrington R., Fan A., Lee E., Spalding J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: A retrospective study. BMC Infect. Dis. 2016;16:1–6. doi: 10.1186/s12879-016-2023-z. PubMed DOI PMC

Hartnett K.P., Jackson B.R., Perkins K.M., Glowicz J., Kerins J.L., Black S.R., Lockhart S.R., Christensen B.E., Beer K.D. A Guide to Investigating Suspected Outbreaks of Mucormycosis in Healthcare. J. Fungi. 2019;5:69. doi: 10.3390/jof5030069. PubMed DOI PMC

The Hindu Govt Declares Mucormycosis as a Notifiable Disease. [(accessed on 29 September 2021)]. Available online: https://www.thehindu.com/news/national/telangana/govt-declares-mucormycosis-as-a-notifiable-disease/article34606579.ece.

Deccan Herald Explained | Covid-19: Mucormycosis or “Black Fungus”—What Is a Notifiable Disease? [(accessed on 29 September 2021)]. Available online: https://www.deccanherald.com/national/explained-covid-19-mucormycosis-or-black-fungus-what-is-a-notifiable-disease-988995.html.

Government of India THE EPIDEMIC DISEASES ACT. [(accessed on 29 September 2021)];1897 Available online: https://legislative.gov.in/sites/default/files/A1897-03.pdf.

Sheraton M., Deo N., Kashyap R., Surani S. A Review of Neurological Complications of COVID-19. Cureus. 2020;12:e8192. doi: 10.7759/cureus.8192. PubMed DOI PMC

Chen X., Laurent S., Onur O.A., Kleineberg N.N., Fink G.R., Schweitzer F., Warnke C. A systematic review of neurological symptoms and complications of COVID-19. J. Neurol. 2020;268:392–402. doi: 10.1007/s00415-020-10067-3. PubMed DOI PMC

Shafi A.M.A., Shaikh S.A., Shirke M.M., Iddawela S., Harky A. Cardiac manifestations in COVID-19 patients—A systematic review. J. Card. Surg. 2020;35:1988–2008. doi: 10.1111/jocs.14808. PubMed DOI PMC

Riad A., Boccuzzi M., Sagiroglu D., Klugar M., Krsek M. Pediatric multisystem inflammatory syndrome temporally associated with SARS-COV-2: Oral manifestations and implications. Int. J. Paediatr. Dent. 2021;31:35–36. doi: 10.1111/ipd.12694. PubMed DOI PMC

Rokkas T. Gastrointestinal involvement in COVID-19: A systematic review and meta-analysis. Ann. Gastroenterol. 2020;33:355–365. doi: 10.20524/aog.2020.0506. PubMed DOI PMC

Tariq R., Saha S., Furqan F., Hassett L., Pardi D., Khanna S. Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clin. Proc. 2020;95:1632–1648. doi: 10.1016/j.mayocp.2020.06.003. PubMed DOI PMC

Wollina U., Karadağ A.S., Rowland-Payne C., Chiriac A., Lotti T. Cutaneous signs in COVID -19 patients: A review. Dermatol. Ther. 2020;33:33. doi: 10.1111/dth.13549. PubMed DOI PMC

Daneshgaran G., Dubin D.P., Gould D.J. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am. J. Clin. Dermatol. 2020;21:1–13. doi: 10.1007/s40257-020-00558-4. PubMed DOI PMC

Riad A., Gomaa E., Hockova B., Klugar M. Oral candidiasis of COVID-19 patients: Case report and review of evidence. J. Cosmet. Dermatol. 2021;20:1580–1584. doi: 10.1111/jocd.14066. PubMed DOI PMC

Hocková B., Riad A., Valky J., Šulajová Z., Stebel A., Slávik R., Bečková Z., Pokorná A., Klugarová J., Klugar M. Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases. J. Clin. Med. 2021;10:581. doi: 10.3390/jcm10040581. PubMed DOI PMC

Riad A., Kassem I., Hockova B., Badrah M., Klugar M. Halitosis in COVID-19 patients. Spec. Care Dent. 2021;41:282–285. doi: 10.1111/scd.12547. PubMed DOI PMC

Riad A., Kassem I., Stanek J., Badrah M., Klugarova J., Klugar M. Aphthous stomatitis in COVID -19 patients: Case-series and literature review. Dermatol. Ther. 2021;34:e14735. doi: 10.1111/dth.14735. PubMed DOI PMC

Singh A., Hussain S., Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:813–822. doi: 10.1016/j.dsx.2021.03.019. PubMed DOI PMC

Hussain S., Baxi H., Jamali M.C., Nisar N., Hussain S. Burden of diabetes mellitus and its impact on COVID-19 patients: A meta-analysis of real-world evidence. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14:1595–1602. doi: 10.1016/j.dsx.2020.08.014. PubMed DOI PMC

Johnson A.K., Ghazarian Z., Cendrowski K.D., Persichino J.G. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med. Mycol. Case Rep. 2021;32:64–67. doi: 10.1016/j.mmcr.2021.03.006. PubMed DOI PMC

Krishna D.S., Raj H., Kurup P., Juneja M. Maxillofacial Infections in Covid-19 Era—Actuality or the Unforeseen: 2 Case Reports. Indian J. Otolaryngol. Head Neck Surg. 2021:1–4. doi: 10.1007/s12070-021-02618-5. PubMed DOI PMC

Centres for Disease Control and Prevention (CDC) Fungal Diseases and COVID-19. [(accessed on 29 September 2021)]; Available online: https://www.cdc.gov/fungal/covid-fungal.html.

Nucci M., Barreiros G., Guimarães L.F., Deriquehem V.A., Castiñeiras A.C., Nouér S.A. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses. 2021;64:152–156. doi: 10.1111/myc.13225. PubMed DOI PMC

Garg D., Muthu V., Sehgal I.S., Ramachandran R., Kaur H., Bhalla A., Puri G.D., Chakrabarti A., Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021;186:289–298. doi: 10.1007/s11046-021-00528-2. PubMed DOI PMC

Salehi M., Ahmadikia K., Mahmoudi S., Kalantari S., Siahkali S.J., Izadi A., Kord M., Manshadi S.A.D., Seifi A., Ghiasvand F., et al. Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility pattern. Mycoses. 2020;63:771–778. doi: 10.1111/myc.13137. PubMed DOI PMC

Riad A., Gad A., Hockova B., Klugar M. Oral candidiasis in non-severe COVID-19 patients: Call for antibiotic stewardship. Oral Surg. 2020:12561. doi: 10.1111/ors.12561. PubMed DOI PMC

Wayback Machine Fungal Diseases and COVID-19 | Centers for Disease Control and Prevention (CDC) [(accessed on 29 September 2021)]; Available online: https://web.archive.org/web/20201204181306/https://www.cdc.gov/fungal/covid-fungal.html.

Hussain S., Baxi H., Riad A., Klugarová J., Pokorná A., Slezáková S., Líčeník R., Najmi A.K., Klugar M. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. Int. J. Environ. Res. Public Health. 2021;18:10340. doi: 10.3390/ijerph181910340. PubMed DOI PMC

Riad A., Shabaan A.A., Issa J., Ibrahim S., Amer H., Mansy Y., Kassem I., Kassem A.B., Howaldt H.-P., Klugar M., et al. COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. J. Fungi. 2021;7:837. doi: 10.3390/jof7100837. PubMed DOI PMC

Ramaswami A., Sahu A.K., Kumar A., Suresh S., Nair A., Gupta D., Chouhan R., Bhat R., Mathew R., A Majeed J., et al. COVID-19-associated mucormycosis presenting to the Emergency Department—An observational study of 70 patients. Qjm Int. J. Med. 2021;114:464–470. doi: 10.1093/qjmed/hcab190. PubMed DOI PMC

Mishra Y., Prashar M., Sharma D., Akash, Kumar V., Tilak T. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:102196. doi: 10.1016/j.dsx.2021.102196. PubMed DOI PMC

Patel A., Agarwal R., Rudramurthy S.M., Shevkani M., Xess I., Sharma R., Savio J., Sethuraman N., Madan S., Shastri P., et al. Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India—Volume 27, Number 9—September 2021—Emerging Infectious Diseases journal—CDC. Emerg. Infect. Dis. 2021;27:2349–2359. doi: 10.3201/eid2709.210934. PubMed DOI PMC

Selarka L., Sharma S., Saini D., Sharma S., Batra A., Waghmare V.T., Dileep P., Patel S., Shah M., Parikh T., et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021;64:1253–1260. doi: 10.1111/myc.13353. PubMed DOI PMC

Singh A.K., Singh R., Joshi S.R., Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021;15:102146. doi: 10.1016/j.dsx.2021.05.019. PubMed DOI PMC

Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. PubMed DOI PMC

Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B., et al. Meta-analysis of Observational Studies in EpidemiologyA Proposal for Reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008. PubMed DOI

Elliott J.H., Turner T., Clavisi O., Thomas J., Higgins J., Mavergames C., Gruen R.L. Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap. PLoS Med. 2014;11:e1001603. doi: 10.1371/journal.pmed.1001603. PubMed DOI PMC

Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557. doi: 10.1136/bmj.327.7414.557. PubMed DOI PMC

Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schünemann H.J. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. doi: 10.1136/bmj.39489.470347.AD. PubMed DOI PMC

Bayram N., Ozsaygılı C., Sav H., Tekin Y., Gundogan M., Pangal E., Cicek A., Özcan I. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn. J. Ophthalmol. 2021;65:515–525. doi: 10.1007/s10384-021-00845-5. PubMed DOI PMC

Nasir N., Farooqi J., Mahmood S.F., Jabeen K. COVID-19 associated mucormycosis: A life-threatening complication in patients admitted with severe to critical COVID-19 from Pakistan. Clin. Microbiol. Infect. 2021;27:1704–1707. doi: 10.1016/j.cmi.2021.07.038. PubMed DOI PMC

Peng J., Wang Q., Mei H., Zheng H., Liang G., She X., Liu W. Fungal co-infection in COVID-19 patients: Evidence from a systematic review and meta-analysis. Aging. 2021;13:7745–7757. doi: 10.18632/aging.202742. PubMed DOI PMC

Petrikkos G., Skiada A., Lortholary O., Roilides E., Walsh T.J., Kontoyiannis D.P. Epidemiology and Clinical Manifestations of Mucormycosis. Clin. Infect. Dis. 2012;54((Suppl. S1)):S23–S34. doi: 10.1093/cid/cir866. PubMed DOI

Corzo-León D.E., Chora-Hernández L.D., Rodríguez-Zulueta A.P., Walsh T.J. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med. Mycol. 2018;56:29–43. doi: 10.1093/mmy/myx017. PubMed DOI

Dolatabadi S., Ahmadi B., Rezaei-Matehkolaei A., Zarrinfar H., Skiada A., Mirhendi H., Nashibi R., Niknejad F., Nazeri M., Rafiei A., et al. Mucormycosis in Iran: A six-year retrospective experience. J. Med. Mycol. 2018;28:269–273. doi: 10.1016/j.mycmed.2018.02.014. PubMed DOI

Pagano L., Valentini C., Posteraro B., Girmenia C., Ossi C., Pan A., Candoni A., Nosari A., Riva M., Cattaneo C., et al. Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed Animale and European Confederation of Medical Mycology) J. Chemother. 2009;21:322–329. doi: 10.1179/joc.2009.21.3.322. PubMed DOI

Lanternier F., Dannaoui E., Morizot G., Elie C., Garcia-Hermoso D., Huerre M., Bitar D., Dromer F., Lortholary O., The French Mycosis Study Group A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005–2007) Clin. Infect. Dis. 2012;54:S35–S43. doi: 10.1093/cid/cir880. PubMed DOI

Petrikkos G., Skiada A., Sambatakou H., Toskas A., Vaiopoulos G., Giannopoulou M., Katsilambros N. Mucormycosis: Ten-Year Experience at a Tertiary-Care Center in Greece. Eur. J. Clin. Microbiol. Infect. Dis. 2003;22:753–756. doi: 10.1007/s10096-003-1035-y. PubMed DOI

Nasir N., Farooqi J., Mahmood S.F., Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses. 2020;63:766–770. doi: 10.1111/myc.13135. PubMed DOI PMC

Wagner C., Griesel M., Mikolajewska A., Mueller A., Nothacker M., Kley K., Metzendorf M.-I., Fischer A.-L., Kopp M., Stegemann M., et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst. Rev. 2021;2021 doi: 10.1002/14651858.cd014963. PubMed DOI PMC

National Institutes of Health (NIH) Corticosteroids. [(accessed on 30 September 2021)]; Available online: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/

Mammen M.J., Aryal K., Alhazzani W., Alexander P.E. Corticosteroids for patients with acute respiratory distress syndrome: A systematic review and meta-analysis of randomized trials. Polish Arch. Intern. Med. 2020;130:276–286. doi: 10.20452/pamw.15239. PubMed DOI

Moorthy A., Gaikwad R., Krishna S., Hegde R., Tripathi K.K., Kale P.G., Rao P.S., Haldipur D., Bonanthaya K. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. J. Maxillofac. Oral Surg. 2021;20:418–425. doi: 10.1007/s12663-021-01532-1. PubMed DOI PMC

Kontoyiannis D.P., Wessel V.C., Bodey G.P., Rolston K.V.I. Zygomycosis in the 1990s in a Tertiary-Care Cancer Center. Clin. Infect. Dis. 2000;30:851–856. doi: 10.1086/313803. PubMed DOI

Jiménez C., Lumbreras C., Aguado J.M., Loinaz C., Paseiro G., Andrés A., Morales J.M., Sánchez G., García I., Del Palacio A., et al. Successful Treatment of Mucor Infection After Liver or Pancreas-Kidney Transplantation. Transplantation. 2002;73:476–480. doi: 10.1097/00007890-200202150-00026. PubMed DOI

Arastehfar A., Carvalho A., Van De Veerdonk F.L., Jenks J.D., Koehler P., Krause R., Cornely O.A., Perlin D.S., Lass-Flörl C., Hoenigl M. COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment. J. Fungi. 2020;6:91. doi: 10.3390/jof6020091. PubMed DOI PMC

Montrucchio G., Lupia T., Lombardo D., Stroffolini G., Corcione S., De Rosa F.G., Brazzi L. Risk factors for invasive aspergillosis in ICU patients with COVID-19: Current insights and new key elements. Ann. Intensiv. Care. 2021;11:1–11. doi: 10.1186/s13613-021-00923-4. PubMed DOI PMC

Ritter L.A., Britton N., Heil E.L., Teeter W.A., Murthi S.B., Chow J.H., Ricotta E., Chertow D.S., Grazioli A., Levine A.R. The Impact of Corticosteroids on Secondary Infection and Mortality in Critically Ill COVID-19 Patients. J. Intensiv. Care Med. 2021;36:1201–1208. doi: 10.1177/08850666211032175. PubMed DOI PMC

Hong H.-L., Lee Y.-M., Kim T., Lee J.-Y., Chung Y.-S., Kim M.-N., Kim S.-H., Choi S.-H., Kim Y.S., Woo J.H., et al. Risk Factors for Mortality in Patients with Invasive Mucormycosis. Infect. Chemother. 2013;45:292–298. doi: 10.3947/ic.2013.45.3.292. PubMed DOI PMC

Vaezi A., Moazeni M., Rahimi M.T., De Hoog S., Badali H. Mucormycosis in Iran: A systematic review. Mycoses. 2016;59:402–415. doi: 10.1111/myc.12474. PubMed DOI

Palejwala S.K., Zangeneh T.T., Goldstein S.A., Lemole G.M. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. Surg. Neurol. Int. 2016;7:61. doi: 10.4103/2152-7806.182964. PubMed DOI PMC

Donnelly J.P., Chen S.C., Kauffman C.A., Steinbach W.J., Baddley J.W., Verweij P.E., Clancy C.J., Wingard J.R., Lockhart S.R., Groll A.H., et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis. 2019;71:1367–1376. doi: 10.1093/cid/ciz1008. PubMed DOI PMC

De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O., Kauffman C.A., et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008;46:1813–1821. doi: 10.1086/588660. PubMed DOI PMC

Pagano L., Mayor S. Invasive fungal infections in high-risk patients: Report from TIMM-8 2017. Futur. Sci. OA. 2018;4:FSO307. doi: 10.4155/fsoa-2018-0019. PubMed DOI PMC